As per NPPA Order S.O. 5690(E) dated 17 October 2026, the trade margin on 137 non-scheduled anti-cancer medicines is capped at 30%. Hetero’s revised MRPs take effect on 9 November 2026.
Patients and partners with questions about the revised prices are welcome to speak to their doctor, pharmacist or hospital.
Source: NPPA Order S.O. 5690(E), The Gazette of India, 17 October 2026.
The FRENZA Division of Hetero Healthcare is focused on addressing healthcare needs across neuropsychiatry and mental health, with a portfolio of therapeutic solutions designed to support the management of neurological, behavioural, and psychiatric conditions. The division aims to assist healthcare professionals in providing sustained and patient-centric care for conditions that can significantly influence emotional well-being, cognitive health, and everyday functioning.
Its therapeutic portfolio encompasses areas such as depression, anxiety disorders, schizophrenia and other psychotic disorders, bipolar disorder, epilepsy and seizure management, neuropathic conditions, and related neurological and psychiatric concerns. With treatment needs often varying from patient to patient, FRENZA supports a comprehensive approach to both symptom management and long-term care.
Backed by Hetero Healthcare’s commitment to quality, accessibility, innovation, and patient-centric healthcare, FRENZA strives to provide dependable therapeutic options across the neuropsychiatry spectrum. Through its focused portfolio and commitment to evolving clinical needs, the division aims to support healthcare professionals in improving treatment experiences, enhancing patient well-being, and contributing to better quality of life.
View by-
